These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 32430489)

  • 61. PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.
    Costa C; Wang Y; Ly A; Hosono Y; Murchie E; Walmsley CS; Huynh T; Healy C; Peterson R; Yanase S; Jakubik CT; Henderson LE; Damon LJ; Timonina D; Sanidas I; Pinto CJ; Mino-Kenudson M; Stone JR; Dyson NJ; Ellisen LW; Bardia A; Ebi H; Benes CH; Engelman JA; Juric D
    Cancer Discov; 2020 Jan; 10(1):72-85. PubMed ID: 31594766
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
    de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE
    Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788
    [No Abstract]   [Full Text] [Related]  

  • 63. Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.
    Hou JY; Rodriguez-Gabin A; Samaraweera L; Hazan R; Goldberg GL; Horwitz SB; McDaid HM
    PLoS One; 2013; 8(2):e54103. PubMed ID: 23390495
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
    Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
    Ambrosini G; Do C; Tycko B; Realubit RB; Karan C; Musi E; Carvajal RD; Chua V; Aplin AE; Schwartz GK
    Cancer Res; 2019 May; 79(9):2415-2425. PubMed ID: 30885979
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
    Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
    Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer.
    Shi X; Li H; Shi A; Yao H; Ke K; Dong C; Zhu Y; Qin Y; Ding Y; He YH; Liu X; Li L; Lei L; Hai Q; Chen W; Leung KS; Wong MH; Kung HF; Lin MC
    Oncol Rep; 2018 Sep; 40(3):1592-1600. PubMed ID: 29956794
    [TBL] [Abstract][Full Text] [Related]  

  • 70. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.
    Sriramareddy SN; Faião-Flores F; Emmons MF; Saha B; Chellappan S; Wyatt C; Smalley I; Licht JD; Durante MA; Harbour JW; Smalley KSM
    Cancer Gene Ther; 2022 Dec; 29(12):1840-1846. PubMed ID: 35332245
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X; Park S; Lee WK; Cheng SY
    Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
    Harada M; Morikawa M; Ozawa T; Kobayashi M; Tamura Y; Takahashi K; Tanabe M; Tada K; Seto Y; Miyazono K; Koinuma D
    Cancer Sci; 2019 Jan; 110(1):209-220. PubMed ID: 30343527
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER
    Shee K; Jiang A; Varn FS; Liu S; Traphagen NA; Owens P; Ma CX; Hoog J; Cheng C; Golub TR; Straussman R; Miller TW
    FASEB J; 2019 Feb; 33(2):1644-1657. PubMed ID: 30161001
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.
    Lau PKH; Cullinane C; Jackson S; Walker R; Smith LK; Slater A; Kirby L; Patel RP; von Scheidt B; Slaney CY; McArthur GA; Sheppard KE
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944961
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
    Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
    Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
    Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
    Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
    [TBL] [Abstract][Full Text] [Related]  

  • 78. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer.
    Kase AM; Gleba J; Miller JL; Miller E; Petit J; Barrett MT; Zhou Y; Parent EE; Cai H; Knight JA; Orme J; Reynolds J; Durham WF; Metz TM; Meurice N; Edenfield B; Alasonyalilar Demirer A; Bilgili A; Hickman PG; Pawlush ML; Marlow L; Wickland DP; Tan W; Copland JA
    Mol Cancer Ther; 2024 Jun; 23(6):823-835. PubMed ID: 38442920
    [TBL] [Abstract][Full Text] [Related]  

  • 80. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
    Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
    JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.